April 04, 2018
1 min read

FDA grants priority review to dacomitinib for EGFR-positive non-small cell lung cancer

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted priority review to dacomitinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor-activating mutations, according to the agent’s manufacturer.

Dacomitinib (PF-00299804, Pfizer) is a once-daily oral pan-human EGFR tyrosine kinase inhibitor.

The FDA based this priority review designation on the results from the phase 3 ARCHER 1050 trial of dacomitinib compared with gefitinib (Iressa, AstraZeneca).

Median PFS reached 14.7 months among patients randomly assigned to dacomitinib (n = 227) compared with 9.2 months among patients assigned gefitinib (n = 225), resulting in a 41% reduction in risk for disease progression or death (HR = 0.59; 95% CI, 0.47-0.74).

As HemOnc Today previously reported, results from this study were presented at the ASCO Annual Meeting last year.

“While significant progress has been made in the treatment of patients with non-small cell lung cancers harboring EGFR-activating mutations, it remains a challenging disease and new treatment options are needed,” Mace Rothenberg, MD, chief development officer of oncology at Pfizer Global Product Development, said in a press release. “In the pivotal clinical trial that supports these applications, dacomitinib showed clinically meaningful improvement in PFS over gefitinib, one of the first EGFR-targeted therapies to demonstrate activity in this disease.”

The adverse events observed with dacomitinib appeared consistent with findings from previous trials. The most common adverse events included diarrhea (87%), nail changes (62%), rash/dermatitis acneiform (49%) and mouth sores (44%). The most common grade 3 adverse events included rash (14%) and diarrhea (8%). For dacomitinib-treated patients, 2% had grade 4 adverse events. Additionally, there was one case of grade 5 diarrhea and one case of grade 5 liver disease.

Ten percent of patients randomly assigned to dacomitinib discontinued treatment due to adverse events compared with 7% of treated with gefitinib.